{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV13&page=2", "query": { "intervention": "PCV13", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV13&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T13:18:31.888Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06740630", "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chickenpox" ], "interventions": [ { "name": "Investigational varicella vaccine_Lot 1", "type": "BIOLOGICAL" }, { "name": "Investigational varicella vaccine_Lot 2", "type": "BIOLOGICAL" }, { "name": "Investigational varicella vaccine_Lot 3", "type": "BIOLOGICAL" }, { "name": "Marketed varicella vaccine_Lot 1", "type": "BIOLOGICAL" }, { "name": "Marketed varicella vaccine_Lot 2", "type": "BIOLOGICAL" }, { "name": "MMR vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis A vaccine", "type": "BIOLOGICAL" }, { "name": "PCV (pneumococcal conjugate vaccine) 13", "type": "BIOLOGICAL" }, { "name": "PCV 20", "type": "BIOLOGICAL" }, { "name": "Vaxneuvance", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 1840, "start_date": "2025-01-10", "completion_date": "2027-05-17", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 59, "location_summary": "Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Sherwood", "state": "Arkansas" }, { "city": "Canoga Park", "state": "California" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06740630" }, { "nct_id": "NCT03859687", "title": "Trial of Antibody Responses by Vitamin Supplementation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Vitamin A supplementation", "type": "BIOLOGICAL" }, { "name": "No vitamin A supplementation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": "4 Years", "sex": "ALL", "summary": "1 Year to 4 Years" }, "enrollment_count": 22, "start_date": "2019-08-19", "completion_date": "2025-07-10", "has_results": false, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03859687" }, { "nct_id": "NCT01282216", "title": "Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Transplant-Related Cancer" ], "interventions": [ { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "PCV13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2011-04", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2019-05-30", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282216" }, { "nct_id": "NCT03439657", "title": "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Herpes Zoster" ], "interventions": [ { "name": "HZ/su vaccine GSK1437173A", "type": "BIOLOGICAL" }, { "name": "Prevenar13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 913, "start_date": "2018-04-12", "completion_date": "2020-03-03", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 3, "location_summary": "Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina", "locations": [ { "city": "Marlborough", "state": "Massachusetts" }, { "city": "Salisbury", "state": "North Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439657" }, { "nct_id": "NCT03621670", "title": "Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infections, Meningococcal" ], "interventions": [ { "name": "Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)", "type": "BIOLOGICAL" }, { "name": "Prevnar13", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Hiberix", "type": "BIOLOGICAL" }, { "name": "Rotarix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Placebo (saline water)", "type": "BIOLOGICAL" }, { "name": "Prevnar 20", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 1196, "start_date": "2018-07-27", "completion_date": "2024-12-27", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03621670" }, { "nct_id": "NCT01852591", "title": "Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "PCV 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2013-02", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2017-02-02", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01852591" }, { "nct_id": "NCT03547167", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 1515, "start_date": "2018-07-16", "completion_date": "2020-01-20", "has_results": true, "last_update_posted_date": "2021-01-15", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 38, "location_summary": "Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more", "locations": [ { "city": "Chinle", "state": "Arizona" }, { "city": "Fort Defiance", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Whiteriver", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547167" }, { "nct_id": "NCT04745559", "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (TFL)", "High-grade B-cell Lymphoma (HGBCL)", "Follicular Lymphoma" ], "interventions": [ { "name": "Pneumococcal conjugate vaccine (PCV13)", "type": "BIOLOGICAL" }, { "name": "CD19 targeted CAR T Cell Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-02-18", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745559" }, { "nct_id": "NCT04525599", "title": "A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Pneumococcal Disease" ], "interventions": [ { "name": "ASP3772", "type": "BIOLOGICAL" }, { "name": "PCV13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Affinivax, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 75, "start_date": "2020-09-22", "completion_date": "2022-04-06", "has_results": false, "last_update_posted_date": "2022-06-06", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 17, "location_summary": "Bryant, Arkansas • Jonesboro, Arkansas • Anaheim, California + 14 more", "locations": [ { "city": "Bryant", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Madera", "state": "California" }, { "city": "West Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04525599" }, { "nct_id": "NCT03673462", "title": "Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy Volunteers (Meningococcal Infection)" ], "interventions": [ { "name": "Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)", "type": "BIOLOGICAL" }, { "name": "Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)", "type": "BIOLOGICAL" }, { "name": "Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Rotavirus Vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine", "type": "BIOLOGICAL" }, { "name": "Measles, Mumps, and Rubella Virus Vaccine", "type": "BIOLOGICAL" }, { "name": "Varicella Virus Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "89 Days", "sex": "ALL", "summary": "42 Days to 89 Days" }, "enrollment_count": 2797, "start_date": "2018-09-17", "completion_date": "2023-03-16", "has_results": true, "last_update_posted_date": "2023-12-14", "last_synced_at": "2026-09-04T13:18:31.888Z", "location_count": 67, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 56 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03673462" } ] }